PRODUCTS

Catalog Number:RP0006
Recombinant Human TGF-beta 1
Copy Product Information

Size:

50 μg

500 μg

Price:

$704.00

$3050.00

Delivery: Order now, ship in 3 days

Product Details
Product Name Recombinant Human TGF-beta 1 Accesstion Number P01137
Alternative Names Transforming Growth Factor Beta-1; TGF-Beta-1; Latency-Associated Peptide; LAP; TGFB1; TGFB
Description Recombinant Human Transforming Growth Factor Beta 1 is produced by our Mammalian expression system and the target gene encoding Ala279-Ser390 is expressed.
Calculated Molecular Weight Mol Mass:12.8 KDa; APMol Mass:13 KDa, reducing conditions Formulation Lyophilized from a 0.2 μm filtered solution of 50mM Glycine-HCl, 150mM NaCl, pH 2.5.
Endotoxin < 0.01 EU/µg as determined by LAL test. Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Measured by its ability to inhibit the IL-4-dependent proliferation of TF‑1 human erythroleukemic cells. The ED50 for this effect is 4-40 pg/ml. (QC verified)
Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Background Transforming Growth Factor β-1 (TGFβ-1) is a secreted protein which belongs to the TGF-β family. TGFβ-1 is abundantly expressed in bone, articular cartilage and chondrocytes and is increased in osteoarthritis (OA). TGFβ-1 performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The precursor is cleaved into a latency-associated peptide (LAP) and a mature TGFβ-1 peptide. TGFβ-1 may also form heterodimers with other TGFβ family members. It has been found that TGFβ-1 is frequently upregulated in tumor cells. Mutations in this gene results in Camurati-Engelmann disease.
  • Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
  • Measured by its ability to inhibit the IL-4-dependent proliferation of TF‑1 human erythroleukemic cells. The ED50 for this effect is 4-40 pg/ml. (QC verified)